A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

National Taiwan University Hospital /ID# 210993, Taipei City

Duplicate_Icon Cancer Centre /ID# 224084, South Brisbane

UPMC Hillman Cancer Ctr /ID# 222747, Pittsburgh

Virginia Cancer Specialists - Fairfax /ID# 210671, Fairfax

Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid

Hospital Universitario HM Sanchinarro /ID# 212805, Madrid

Carolina BioOncology Institute /ID# 210664, Huntersville

Hospital Universitario Virgen de la Victoria /ID# 221671, Málaga

China Medical University Hospital /ID# 221090, Taichung

Institut de Cancérologie de l'Ouest René Gauducheau /ID# 212880, Saint-Herblain

Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072, Fort Wayne

Centre Jean Perrin /ID# 217911, Clermont-Ferrand

Washington University-School of Medicine /ID# 221399, St Louis

Centre Leon Berard /ID# 217910, Lyon

Highlands Oncology Group, PA /ID# 218863, Springdale

AP-HP - Hopital Bichat - Claude-Bernard /ID# 212869, Paris

Mary Crowley Cancer Research /ID# 210716, Dallas

Institut Curie /ID# 223475, Paris

NEXT Oncology /ID# 210717, San Antonio

St Jude Hospital dba St Joseph /ID# 211130, Santa Rosa

The Chaim Sheba Medical Center /ID# 211699, Ramat Gan

Yale University School of Medicine /ID# 210678, New Haven

Moffitt Cancer Center /ID# 215037, Tampa

Duke Cancer Center /ID# 217641, Durham

Tennessee Oncology-Nashville Centennial /ID# 221400, Nashville

Hospital Universitario Vall d'Hebron /ID# 212804, Barcelona